PROF vs. SMLR, KIDS, CBLL, TMCI, DCTH, BFLY, RXST, SNWV, CLPT, and NPCE
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include Semler Scientific (SMLR), OrthoPediatrics (KIDS), CeriBell (CBLL), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Butterfly Network (BFLY), RxSight (RXST), Sanuwave Health (SNWV), ClearPoint Neuro (CLPT), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.
Profound Medical vs. Its Competitors
Profound Medical (NASDAQ:PROF) and Semler Scientific (NASDAQ:SMLR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.
Semler Scientific has a net margin of 86.20% compared to Profound Medical's net margin of -343.97%. Semler Scientific's return on equity of 43.84% beat Profound Medical's return on equity.
Profound Medical presently has a consensus price target of $11.00, suggesting a potential upside of 142.83%. Semler Scientific has a consensus price target of $81.75, suggesting a potential upside of 166.90%. Given Semler Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Semler Scientific is more favorable than Profound Medical.
In the previous week, Semler Scientific had 2 more articles in the media than Profound Medical. MarketBeat recorded 5 mentions for Semler Scientific and 3 mentions for Profound Medical. Semler Scientific's average media sentiment score of 1.27 beat Profound Medical's score of 1.21 indicating that Semler Scientific is being referred to more favorably in the news media.
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 49.4% of Semler Scientific shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 16.4% of Semler Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Semler Scientific has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.
Profound Medical has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.
Summary
Semler Scientific beats Profound Medical on 16 of the 17 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
This page (NASDAQ:PROF) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access